Mapping Human Protease-activated Receptor 4 (PAR4) Homodimer Interface to Transmembrane Helix 4*

Maria de la Fuente‡, Daniel N. Noble‡, Sheetal Verma‡, and Marvin T. Nieman‡

From the ‡Division of Hematology/Oncology and the §Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106

Background: Protease-activated receptor 4 (PAR4) mediates thrombin signaling on platelets and other cells.
Results: Disruption of the PAR4 homodimer interface interferes with signaling.
Conclusion: Dimerization of PAR4 is critical for signaling.
Significance: The interactions of PAR4 at the plasma membrane may have important functions that regulate signaling.

Thrombin activates platelets by binding and cleaving protease-activated receptors 1 and 4 (PAR1 and PAR4). Because of the importance of PAR4 activation on platelets in humans and mice and emerging roles for PAR4 in other tissues, experiments were done to characterize the interaction between PAR4 homodimers. Bimolecular fluorescence complementation and bioluminescence resonance energy transfer (BRET) were used to examine the PAR4 homodimer interface. In bimolecular fluorescence complementation experiments, PAR4 formed homodimers that were disrupted by unlabeled PAR4 in a concentration-dependent manner, but not by rhodopsin. In BRET experiments, the PAR4 homodimers showed a specific interaction as indicated by a hyperbolic BRET signal in response to increasing PAR4-GFP expression. PAR4 did not interact with rhodopsin in BRET assays. The threshold maximum BRET signal was disrupted in a concentration-dependent manner by unlabeled PAR4. In contrast, rhodopsin was unable to disrupt the BRET signal, indicating that the disruption of the PAR4 homodimer is not due to nonspecific interactions. A panel of rho-PAR4 chimeras and PAR4 point mutants has mapped the dimer interface to hydrophobic residues in transmembrane helix 4. Finally, mutations that disrupted dimer formation had reduced calcium mobilization in response to the PAR4 agonist peptide. These results link the loss of dimer formation to a loss of PAR4 signaling.

The protease-activated receptors (PAR)² are a class of G protein-coupled receptors (GPCR) that are activated by the proteolysis of the N-terminal exodomain (1). Upon proteolysis, the newly formed N terminus acts as a tethered ligand that activates the receptor and initiates signaling cascades through multiple G proteins (Gαq, Gα12, and Gα13) (2, 3). There are four members of this receptor family (PAR1–4) that are expressed on a variety of cells including platelets, endothelial cells, vascular smooth muscle cells, and inflammatory cells. PAR1, 3, and 4 are activated by thrombin, whereas PAR2 is activated by trypsin or tryptase. Other serine proteases like FVIIa, FXa, plasmin, activated protein C, MMP1, MASP-1, and cathepsin G can activate PARs as well (4–10). Unlike conventional G protein-coupled receptors, PARs are irreversibly activated by cleavage of the exodomain; therefore, specific mechanisms are required to turn off PAR signaling (11).

PAR4 has primarily been studied in the context of platelet activation. PAR1 and PAR4 are expressed on human platelets and mediate thrombin activation of platelets. However, on mouse platelets, PAR4 is the signaling thrombin receptor (12, 13). On cells, PAR1 is activated by low concentrations of thrombin (1 nM), whereas PAR4 is activated by higher concentrations of thrombin. However, PAR1 lowers the amount of thrombin required for PAR4 activation when PAR1 and PAR4 are co-expressed on the same cell, as is the case for human platelets (14, 15). PAR1 and PAR4 signaling first appeared to be redundant, but recent data suggest that each has unique pathways for platelet activation (16–18). A major difference in PAR1 and PAR4 signaling is that, upon activation, PAR1 is phosphorylated on key serine residues, and PAR4 is phosphorylated on other serine residues, which results in rapid internalization and degradation of the receptor (11). In contrast, PAR4 is not phosphorylated and does not internalize as rapidly, resulting in a prolonged stimulus (19, 20). The sustained signaling from PAR4 may be required for stable clot formation (21, 22).

In addition to its role in activation of platelets by thrombin, there is increasing evidence of roles for PAR4 in other physiological processes including nociception, colon cancer cell proliferation, cardiac response to ischemia/reperfusion injury, and diabetic arterial plaques (23–26).

In addition to the interaction between PAR1 and PAR4, PAR4 also interacts with the P2Y12 receptor on platelets to alter signaling (27). Recent studies also suggest that other PAR subtypes can interact with one another to alter signaling from these receptors. Kaneider et al. (28) demonstrated that the...
PAR1–PAR2 heterodimers signaled through a different set of G proteins than PAR1, which changed the physiological response of the endothelial cells from barrier disruptive to barrier protective. PAR1 and PAR2 also form heterodimers on smooth muscles cells and regulate their response to arterial injury (29). McLaughlin et al. (30) have also demonstrated that PAR1 homodimers couple to a different set of G proteins than PAR1–PAR3 heterodimers in transfected HEK293 cells. In summary, PARs, like other GPCRs, may form dimers to mediate multiple effects on cells depending on the context.

PAR4 has roles in multiple physiological processes. In addition, PAR4 may be implementing cross-talk between other receptors. To fully understand how PAR4 is signaling to cells, it is imperative to determine the molecular details of how PAR4 is arranged in the membrane of cells. The present study uses independent methods to demonstrate that PAR4 forms homodimers: bimolecular fluorescence complementation (BiFC) and bioluminescence resonance energy transfer (BRET). The present study has also used a panel of chimeric proteins and PAR4 point mutants to map the region on PAR4 required for homodimers to a hydrophobic interface within transmembrane helix 4.

**EXPERIMENTAL PROCEDURES**

**Reagents**—Unless otherwise stated, all of the reagents were from Sigma–Aldrich.

**Cell Culture**—HEK293 cells were from American Type Culture Collection (Bethesda, MD) and cultured in DMEM supplemented with 10% fetal bovine serum (Hyclone, Logan, UT). Cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

**Molecular Cloning**—The human PAR4 cDNA was purchased from UMR cDNA Resource Center. The mouse rhodopsin cDNA (accession number P14509) was provided by Dr. Krzysztof Palczewski (Case Western Reserve University). The restriction enzyme sites HindIII and KpnI were added to PAR4 by PCR to facilitate ligation into the vectors V1 and V2 for BiFC or pLUC-N2 and pGFP2-N2 for BRET. The vectors D2-V1 and D2-V2 were purchased from Addgene (31), and the D2 sequence was replaced with that of PAR4. The vectors pLUC-N2 and pGFP-N2 were purchased from PerkinElmer Life Sciences. The rhodopsin/PAR4 chimeras were generated using overlapping PCR as previously described (32). A detailed list of primers is available by request. Briefly, primers were designed such that the sequence would switch from rhodopsin to PAR4 at the beginning of transmembrane domain (TM) 2 (rho-PAR4-TM2), TM3 (rho-PAR4-TM3), TM4 (rho-PAR4-TM4), TM5 (rho-PAR4-TM5), TM6 (rho-PAR4-TM6), or TM7 (rho-PAR4-TM7) (see Table 1). The resulting chimeras were ligated into the vector pGFP2-N2 (PerkinElmer Life Sciences) for BRET studies. The transmembrane 4 domain swap mutant (rho-PAR4-rho) was made in a similar fashion. Alanine substitution mutants were made using primers that altered the relevant codon(s) to change L2094.58 and L2134.62 (PAR4–2A); L1924.41, L1944.43, M1984.57, and L2024.51 (PAR4–4A); or individual alanine substitutions. The nomenclature is that of Ball esteros and Weinstein (33). For expression without GFP, PAR4 or rhodopsin was ligated into pCDNA3.1. Human PAR4 with an N-terminal T7 epitope (MASMTGGQQMG) has been described (14); T7-rhodopsin was made in a similar fashion. The HA tag (YPYDVPDYA) or V5 tag (GKPIPPMLLGLDST) was added to the N terminus of PAR4 with PCR at amino acid 18 such that the PAR4 signal sequence was removed.

**Bimolecular Fluorescence Complementation**—HEK293 cells were transfected with HA-PAR4-V1 (0.1 μg) and V5-PAR4-V2 (0.01–0.5 μg). For competition experiments, T7-PAR4-pCDNA3.1 or T7-rhodopsin-pCDNA3.1 (0–1 μg) was co-transfected with HA-PAR4-V1 or V5-PAR4-V2 (0.1 μg each). Forty-eight hours following transfection, the cells were removed from plates by rinsing in PBS containing 1% glucose and immediately analyzed for fluorescence complementation or stained with anti-HA or anti-V5 antibodies to determine expression levels. Fluorescence complementation was determined by measuring the mean fluorescence of 10,000 cells using a BD Biosciences LSRII flow cytometer.

**Bioluminescence Resonance Energy Transfer**—For BRET experiments, HEK293 cells (1 × 10^5) were plated on 6-well dishes. The cells were transfected with 0.5 μg of donor plasmid (PAR4-Luc) and increasing amounts (0–5 μg) of acceptor plasmid (PAR4-GFP, rho-GFP, or rho-PAR4-GFP chimeras) (30, 34). For BRET studies with PAR4 point mutants, 0.03 μg of donor plasmid and 0–0.24 μg of acceptor plasmid was used. Emission was measured using a PerkinElmer Life Sciences Victor 3 plate reader equipped with the appropriate BRET2 filter set (410 nm with 80-nm bandpass and 515 nm with 30-nm bandpass; PerkinElmer Life Sciences). Emission at 410 and 515 nm was collected immediately after the addition of 5 μM luciferase substrate (coelenterazine 400a; Biotium Inc., Hayward, CA). BRET signal was calculated by the ratio of emission at 515 nm to emission at 410 nm minus the BRET in the absence of GFP (35). In BRET studies, specific interactions are detected by a hyperbolic increase in BRET signal (ratio of emission at 510/410 nm) as the ratio of GFP-receptor/RLuc-receptor increases (34). In contrast, nonspecific interactions increase linearly. The graphing software Prism was used to choose the best model (hyperbolic versus linear) for each experiment. GFP expression was determined by excitation at 495 nm and emission at 515 nm. Luciferase expression was determined by adding 5 μM coelenterazine H (Invitrogen) and reading total light emission without a filter. The BRET data from three or four independent experiments are pooled and analyzed by global fit to all of the data.

**Flow Cytometry**—Cell surface expression of PAR4, rhodopsin, or rho-PAR4 chimeras was determined by flow cytometry. HEK293 cells in 6-well plates were transfected with 0.5 μg of plasmid and were removed from plates 48 h post-transfection by rinsing with PBS. The cells were incubated with antibodies to PAR4 (32) or rhodopsin (monoclonal antibody B6–30N (36), kindly provided by Dr. Krzysztof Palczewski (Case Western Reserve University)) followed by incubation with species-specific antibodies conjugated to Alexa Fluor 647 (Invitrogen) to detect surface expression distinct from GFP expression. Mean fluorescence was determined by counting 10,000 cells on an LSRII (BD Biosciences) in the Case Comprehensive Cancer Center flow cytometry core. Surface detection of HA-, V5-, or T7-tagged proteins were detected with an HA tag antibody conjugated to Alexa Fluor 647 with 1:50 dilution (6E2; Cell Sig-
Mapping PAR4 Homodimer Interface

FIGURE 1. PAR4 homodimers are detected with BiFC. HEK293 cells were transiently transfected with HA-PAR4-V1 (0.1 μg) and V5-PAR4-V2 (0.01–0.5 μg). Cells were removed from plates 48 h post-transfection and analyzed immediately by flow cytometry to determine fluorescence from BiFC or stained with anti-HA or anti-V5 antibodies. A, the mean fluorescence intensity (MFI) from BiFC is plotted against the ratio of V5-PAR4-V2 to HA-PAR4-V1 expression determined by quantitative flow cytometry. B, the expression level of HA-PAR4-V1 plotted against the expression level of V5-PAR4-V2. C, for competition experiments, unlabeled T7-PAR4 (closed circles) or T7-rhodopsin (open circles) (0–1.0 μg) was co-transfected with HA-PAR4-V1 (0.1 μg) and V5-PAR4-V2 (0.1 μg) and analyzed for BiFC as in A. The expression level of T7-PAR4 and T7-rhodopsin was determined by flow cytometry with an anti-T7 antibody. The data are a global fit to three independent experiments.

RESULTS

PAR4 participates in multiple physiologic processes. However, the molecular assembly of PAR4 in the membrane of cells is not known. To investigate whether PAR4 forms homodimers on cell surfaces, we used BiFC. HEK293 cells were co-transfected with PAR4 fused with the N-terminal region of Venus (V1) or the C-terminal region of Venus (V2) to test for complementation (Fig. 1A). An HA epitope (HA-PAR4-V1) or V5 epitope (V5-PAR4-V2) was added to the N terminus to monitor the expression level of each of the PAR4 constructs. For these experiments, the cells were co-transfected with HA-PAR4-V1 (0.1 μg) and V5-PAR4-V2 (0.01–0.5 μg) (Fig. 1). The cells were washed from plates in PBS with 1% glucose and immediately analyzed by flow cytometry to determine the mean fluorescence resulting from the complementation or stained with anti-HA or V5 antibodies to analyze expression levels. The mean fluorescence intensity from each antibody was converted to antibody binding sites using a quantitative flow cytometry assay (Bangs Laboratories), allowing the direct comparison of the expression of the HA- and V5-tagged PAR4 proteins. These values were used to calculate the V2/V1 ratio in Fig. 1A. The individual split Venus constructs did not have a fluorescence signal above the background of mock transfected cells (data not shown). However, as V5-PAR4-V2 expression increased, the mean fluorescence fit a hyperbolic curve with a plateau at 302 fluorescence units with a 95% confidence interval of 113–491 (Fig. 1A). Importantly, the expression of HA-PAR4-V1 was not altered as the expression of V5-PAR4-V2 increased (Fig. 1B).

To examine the specificity of the interaction that was detected with BiFC, unlabeled T7-PAR4 or T7-rhodopsin (0–1.0 μg) was co-transfected with HA-PAR4-V1 and V5-PAR4-V2 (0.1 μg each) (Fig. 1C). The expression levels of PAR4 and rhodopsin were directly compared with flow cytometry using an antibody to the T7 epitope conjugated to SureLight allophycocyanin. PAR4 was able to disrupt the BiFC in a concentration-dependent manner. In contrast, rhodopsin was unable disrupt the PAR4–PAR4 interaction, even though it was expressed 5-fold higher. It is of note that rhodopsin consistently had a higher expression than PAR4 when equivalent amounts of plasmid were used in the transfection.

We have demonstrated that PAR4 forms homodimers by BiFC. To further validate these studies, we performed BRET. The PAR4 homodimers show a specific interaction as indicated by a hyperbolic BRET signal in response to an increase in the ratio of PAR4-GFP:PAR4-Luc expression (Fig. 2A). In contrast, a nonspecific BRET signal increases linearly with increasing GFP expression. Importantly, PAR4 did not form dimers with rhodopsin (Fig. 2B), indicating the specificity of the PAR4–PAR4 interactions. Rhodopsin was used as an unrelated GPCR to verify that the interactions were not due merely to overexpression of the receptors. Because we were able to detect a strong BRET signal from the PAR4-Luc and PAR4-GFP inter-
action, we sought to disrupt this interaction by competing with unlabeled PAR4 (Fig. 2C). Increasing amounts of PAR4 in pCDNA3.1 (0–2 μg) were co-transfected with the ratio of the PAR4 BRET constructs that gave the threshold maximum BRET signal (0.5 μg of PAR4-Luc and 2.5 μg of PAR4-GFP). Unlabeled PAR4 was able to disrupt the BRET signal in a concentration-dependent manner (Fig. 2C, closed circles). In contrast, rhodopsin was unable to disrupt the BRET signal from the PAR4 homodimer (Fig. 2C, open circles), indicating that the disruption of the PAR4 homodimer with PAR4 is not due to nonspecific interactions.

To fully understand the interaction between PAR4 homodimers, we initiated investigations to map the homodimer interface. We have demonstrated that PAR4 does not interact with rhodopsin using BRET studies (Fig. 2B). To take advantage of this observation, we generated a series of rhodopsin-PAR4 chimeras that have the junction at the beginning of transmembrane (TM) helix 2, 3, 4, 5, 6, or 7 (Table 1).

The boundaries for the transmembrane helices for PAR4 were determined by comparing the amino acid sequence with that of rhodopsin using the program T-coffee (39, 40). Because we are able to detect a strong interaction using BRET for PAR4 homodimers but not with heterodimers between PAR4 and rhodopsin, the strategy for these experiments was to use the panel of chimeras to determine when dimer formation is restored. Because these chimeras are not naturally occurring molecules, initial experiments examined the surface expression of these chimeras by flow cytometry (Fig. 3). PAR4-Luc and PAR4-GFP were detected with a goat polyclonal antibody directed to PAR4 (29) and a secondary antibody conjugated to Alexa Fluor 647, which allowed specific detection of PAR4 on the cell surface at comparable levels. To examine the interaction of the rho-PAR4 chimeras with PAR4-wt, HEK293 cells were transfected with PAR4-Luc (0.5 μg) and PAR4-GFP (0–5.0 μg) or rho-GFP (0–5.0 μg) (Fig. 4, A–F). Forty-eight hours post-transfection, the cells were analyzed for GFP expression, luciferase expression, and BRET. The data are from three or four independent experiments, in which all points were analyzed by global fit to a hyperbolic or linear curve. C, PAR4 homodimers are disrupted by expression of unlabeled PAR4. PAR4-Luc (0.5 μg) and PAR4-GFP (2.5 μg) were transfected in to HEK293 cells for BRET assays as described in A with increasing amounts of unlabeled PAR4 (closed circles) or rhodopsin (open circles). The data are from three independent experiments, and the error bars represent the standard deviation; the apparent absence of error bars indicates a small standard deviation.

We have narrowed the PAR4 homodimer interface to a 56-amino acid region between the start of TM4 and TM5. To determine whether TM4 was sufficient to interact with PAR4, we generated a chimera in which the TM4 of rhodopsin was replaced with that of PAR4 (Fig. 5A). The rho-PAR4-rh chimeras was tested in BRET experiments, and it showed a specific interaction with PAR4 (Fig. 5B).

We next wanted to understand the structural basis for the homodimer interface. Because the structure of PAR4 is not known, we generated models using Swiss Modeler (Fig. 6A) (41–43). The models are in good agreement with our experimental data in that transmembrane helix 4 has residues that are directed away from the other helices, making them accessible for potential interactions with adjacent PAR4 molecules. An interesting feature of TM4 is a series of leucine residues that are directed outward. The TM4 between PAR4 and rhodopsin were aligned using the alignment program T-coffee (Fig. 6B). This alignment is based on the arrangement of all seven transmembrane helices.

Our data using the rhodopsin/PAR4 chimeras and the PAR4 model strongly suggest that transmembrane helix 4 is the homodimer interface. Studies next directly examined the influence of the hydrophobic residues identified in the PAR4 model as a potential interface (L1924.4, L1944.443, M1984.447, L2024.5, L2094.58, and L2134.62). In addition, we wanted to minimize the influence of overexpression, which may force nonphysiologic interactions to occur. Therefore, an HA epitope (HA-PAR4-Luc) or V5 epitope (V5-PAR4-GFP) was added to allow us to determine the expression levels of each PAR4 on the surface of cells. Initial studies determined the minimum amount of plasmid required to achieve sufficient expression for the BRET assays (Fig. 7). The expression levels were determined using antibodies to HA or V5 tags and analyzed by flow cytometry (Fig. 7). The minimum amount of HA-PAR4-Luc plasmid required for detection was 0.03 μg. Similar to the BiFC experiments (Fig. 1B), increasing V5-PAR4-GFP did not alter HA-PAR4-Luc expression (Fig. 7C). The BRET experiments with PAR4 wild type were repeated using the minimum amount of plasmid (0.03 μg for HA-PAR4-Luc). The V5-PAR4-GFP
phobic residues identified in TM4 act as a hydrophobic interaction interface. To investigate whether these residues are acting in concert or whether individual residues were supporting dimerization, each of the four residues were mutated individually. For each of the point mutations, the binding curve and the maximum BRET signal were unchanged from wild type PAR4 (Table 2). These data indicate that the hydrophobic residues identified in TM4 act as a hydrophobic interface to mediate homodimers and that mutating a single residue is insufficient to disrupt dimerization.

Finally, experiments were designed to determine whether disrupting the PAR4 homodimers had a functional consequence. For these studies, HEK293 cells were transfected with V5-PAR4-wt, V5-PAR4–2A, or V5-PAR4–4A in pCNDA3.1. The expression level was verified by flow cytometry. The mean fluorescence was similar for PAR4-wt (1960 ± 629) and PAR4–2A (2064 ± 560, p = 0.91). The expression of PAR4–4A (1397 ± 422, p = 0.50) was also similar to PAR4-wt. These data agree with the GFP tagged PAR4 mutants in which no differences in expression were observed. Studies next analyzed the ability of each PAR4 construct to mobilize intracellular calcium in response to the PAR4-activating peptide (AYPGKF) (Fig. 9). V5-PAR4–2A had slightly reduced Ca2+ mobilization compared with V5-PAR4-wt. However, V5-PAR4–4A had drastically reduced Ca2+ mobilization. These data correlate the loss of dimer formation to a loss of signaling function for PAR4.

**DISCUSSION**

The current report demonstrates that PAR4 forms homodimers and maps the PAR4 homodimer interface to a series of hydrophobic residues in transmembrane helix 4. The dimerization of PAR4 was determined by independent techniques: BIFC and BRET. The dimerization was specific in that PAR4 did not heterodimerize with rhodopsin, another GPCR from the same class of GPCRs. Further, the current report shows that point mutations that disrupt PAR4 homodimers also impair signaling as measured by calcium mobilization.

**G protein-coupled receptors** have seven transmembrane domains that, when stimulated, signal via heterotrimeric G proteins, which are linked to many intracellular signaling pathways (44). Because of the complex arrangement of GPCRs in the membranes of cells, there has been much debate regarding the molecular assembly of GPCRs in vivo (45, 46). The traditional views were that the signaling GPCR occurred with the 1:1 complex with the intracellular G protein. In support of this view, recent studies with a reconstituted system demonstrate that a monomeric β2-adrenergic receptor was able to bind agonists with high affinity (47). Importantly, in this system, the binding of agonists was able to mediate rapid exchange of nucleotide from the G, heterotrimer, demonstrating that monomers of the β2-adrenergic receptor are functional. Other studies have used the same high-density lipoprotein (HDL) disks to demonstrate that bovine rhodopsin is also capable of signaling as a monomer (48). Therefore, on a biophysical level, two prototypical GPCRs
(β2-adrenergic receptor and rhodopsin) are functional as monomers in a minimal system.

There is also a growing body of evidence suggesting that GPCRs function as oligomeric structures in the plasma membrane of cells (49, 50). The most compelling evidence that GPCRs form oligomers in vivo is the high resolution crystal structure of one of the most well studied GPCRs, rhodopsin (45, 50). When the structure of rhodopsin is compared with models of Gt/α subunits that are based on several lines of biochemical analysis, the oligomeric structure of rhodopsin can be modeled to interact with oligomers of Gt/α (45). Recently, a heteropentameric complex consisting of two rhodopsin molecules and one Gt complex purified from native bovine retinas was characterized biochemically and by scanning transmission electron microscopy (51). These studies provide the most compelling data to date regarding the functionality of GPCR dimers in native tissues. As more is learned about the arrangement of PAR4 in the membrane, it will be important to consider how dimer or oligomer formation may alter PAR4 activity. The current report provides a key starting point for analyzing PAR4 in native tissues.

Although there has been recent progress in methodologies to study the structural properties of GPCRs (52), there is little or no structural data for most GPCRs. Therefore, we must rely on biochemical data and molecular models to define interaction partners and their interaction surfaces. The current report maps the homodimer interface of PAR4 to transmembrane...
helix 4. In molecular models, transmembrane helix 4 of PAR4 has several leucine residues that are directed away from the other helices that may allow these side chains to mediate dimerization (Fig. 8A). The membrane leucine zipper has been described for other membrane proteins such as E-cadherin, erythropoietin, and DDR1 (53–56). However, one must be cautious in drawing general conclusions based on results from single membrane domain-containing proteins to GPCRs, which have seven transmembrane domains. In other GPCRs, such as the dopamine D2 receptor, rhodopsin, and Ste2, TM4 is also at the homodimer interface (49, 57, 58). However, GPCRs use other regions in addition to or instead of TM4 for dimer interactions (59). A recent mutagenesis study with the M3 muscarinic receptor demonstrated that multiple interfaces are possible with the M3 receptor dimer/oligomer (60). Molecular models and biochemical data suggest TM4:TM4, TM5:TM5, TM6:TM7, TM4:TM5, and TM1:TM2 interfaces for the M3 receptor. As the authors of this study suggest, these interfaces may be in dynamic equilibrium. Another example, the dopamine D2 receptor forms oligomers with two interfaces, TM1 and TM4. Our data do not support TM1 as a homodimer interface for PAR4. However, in the PAR4 model, TM1 is angled and may have a smaller potential interface (Fig. 8A). The smaller interface may have weaker interactions that play a role in oligomer formation.

PAR1 has been well studied in human platelet activation by thrombin. However, there is a growing appreciation for the role of PAR4 in platelet activation. The sustained intracellular Ca²⁺ mobilization as a result of PAR4 stimulation may be required for stable clot formation (20–22). Further, PAR4 cooperates...
with the P2Y12 receptor to mediate platelet aggregation (16). In contrast, PAR1-mediated platelet aggregation is independent of P2Y12 signaling. PAR1 signals through PI3K and phosphati
dic acid formed by phospholipase D (17, 61). Inhibitors to PI3K or phospholipase D do not disrupt PAR4 signaling. Fur
ther, PAR4 activation is required for full spreading of platelets on fibrinogen in response to α-thrombin in a p38- and ERK1/
2-dependent manner (22). These data suggest that PAR1 and PAR4 stimulate different signaling pathways in platelets and
likely cooperate to mediate the complete response of the platelets to thrombin. Understanding the arrangement of these
receptors in the membrane may shed light on these unique signaling pathways in platelets.

In addition to expression on platelets, PAR4 is also expressed in smooth muscle cells, endothelial cells, cardiac tissue, brain,
and other neurological tissues. Dangwal et al. (26) demonstrated that PAR4 expression on carotid artery plaques and
saphenous vein smooth muscle cells in diabetic patients was increased compared with normal controls. These observations
were supported by in vitro experiments in which human sapheno
nous vein smooth muscle cells up-regulated PAR4 expression
when grown in the presence of high glucose (26). In cardiac
tissue, inhibition of PAR4 with two independent antagonists was
cardioprotective in a rat ischemia/reperfusion model (23). Inhibiting PAR4 elicited cell survival pathways through PI3K/
Akt, ERK1/2, nitric-oxide synthase, and K_ATP channels in an
adenosine receptor-mediated pathway (23). In addition to roles
in cardiovascular tissues, PAR4 has been implicated in nocicep
tion (24, 25). However, the details appear to be tissue-specific.
For example, in dorsal root ganglia, PAR4 sensitized TRPV1,
resulting in the release of calcitonin gene-related peptide (25).
In other studies, PAR4 sensitization was independent of TRPV1
(24). In contrast, PAR4 stimulation inhibited visceral pain
induced by PAR2 and TRPV4 agonists, and PAR4−/− mice had
increased pain response compared with wild type controls (62).
Taken together, these recent studies provide evidence that
PAR4 has roles in a number of physiological processes in addi
tion to its well studied role in platelet activation.

PAR1 co-expression with PAR4 enhances thrombin activation
of PAR4 on human platelets and transfected cells (14, 15).
In addition, the possibility exists that PAR4 interacts with other
PARs or other receptors in other tissues. One example is the
recent study by Li et al. (27) that describes a signaling interac
tion between PAR4 and the P2Y12 receptor. It will be important
to examine the role of PAR4 dimerization in the context of
these new roles ascribed to PAR4. The current report details the
PAR4 homodimer interface and provides the methodology to
examine the heterodimer interface with PAR1 or other recep
tors. Future studies will need to examine the formation of
homodimers in the context of these potential heterodimer
interactions. An important question to be considered in these
studies is the relative affinity for homodimers versus het
erodimers. In addition to the relative binding affinities, the
dynamics of these interactions are also of interest.

The present study provides a detailed analysis of the PAR4
homodimer. Understanding the molecular details of receptor-
receptor interactions may provide insights for the development
of pharmacological agents that specifically target the receptor
dimer, disrupt the dimer formation, or both. These pharmaco
logical agents may be an effective add on therapy for patients
who do not respond well to current antiplatelet therapies (63).
In addition, as novel roles for PAR4 continue to be uncovered,
there may also be new opportunities for pharmacological
intervention.

Acknowledgments—We thank Michele Mumaw and Amal Arachiche for helpful suggestions and editing of the manuscript.

REFERENCES
1. Coughlin, S. R. (2000) Thrombin signalling and protease-activated recep
tors. Nature 407, 258–264
2. Swift, S., Sheridan, P. J., Covic, L., and Kuliopulos, A. (2000) PAR1 throm
bin receptor–G protein interactions. Separation of binding and coupling
determinants in the Gα subunit. J. Biol. Chem. 275, 2627–2635
3. Steinhoff, M., Buddenkotte, J., Shipacovitch, V., Rattenholl, A., Moor
mann, C., Vergouolle, N., Lugter, T. A., and, and Hollemberg, M. D. (2005) Pro
teinase-activated receptors. Transducers of proteinase-mediated signal
ing in inflammation and immune response. Endocr. Rev. 26, 1–43
4. Kuliopulos, A., Covic, L., Seeley, S. K., Sheridan, P. J., Helin, J., and,
Costello, C. E. (1999) Plasmin desensitization of the PAR1 thrombin recep
tor. Kinetics, sites of truncation, and implications for thrombolytic therapy.
Biochemistry 38, 4572–4585
5. Riewald, M., Petrovan, R. J., Donner, A., and, Ruf, W. (2003) Activated
protein C signals through the thrombin receptor PAR1 in endothelial cells.
J. Endotoxin. Res. 9, 317–321
6. Ruf, W., Dorflueuter, A., and, Riewald, M. (2003) Specificity of coagulation
factor signaling. J. Thromb. Haemost. 1, 1495–1503
7. Quinton, T. M., Kim, S., Derian, C. K., Jin, J., and, Kunapuli, S. P. (2004) Plasmin-mediated activation of platelets occurs by cleavage of protease
activated receptor 4. J. Biol. Chem. 279, 18434–18439
8. Sambrano, G. R., Huang, W., Faruqui, T., Mahrus, S., Craik, C., and,
Coughlin, S. R. (2000) Cathepsin G activates protease-activated receptor-4 in
human platelets. J. Biol. Chem. 275, 6819–6823
9. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and, Kuliopulos, A.
(2005) PAR1 is a matrix metalloproteinase-1 receptor that promotes inva
sion and tumorigenesis of breast cancer cells. Cell 120, 303–313
10. Megyeri, M., Makó, V., Beinrohr, L., Doleschall, Z., Prohászka, Z., Cerve
nak, L., Závodszky, P., and, Gál, P. (2009) Complement protease MASP-1
promotes human endothelial cells. PAR4 activation is a link between com
plement and endothelial function. J. Immunol. 183, 3409–3416
11. Arora, P., Ricks, T. K., and, Trejo, J. (2007) Protease-activated receptor
signalling, endocytic sorting and dysregulation in cancer. J. Cell Sci. 120,
921–928
12. Nakajishi-Matsui, M., Zheng, Y. W., Sulciner, D. J., Weiss, E. J., Ludeman,
M. J. and, Coughlin, S. R. (2000) PAR3 is a cofactor for PAR4 activation by
thrombin. Nature 404, 609–613
13. Sambrano, G. R., Weiss, E. J., Zheng, Y. W., Huang, W., and, Coughlin, S. R.
(2001) Role of thrombin signalling in platelets in haemostasis and thrombo
sis. Nature 413, 74–78
14. Nieman, M. T. (2008) Protease-activated receptor 4 uses anionic residues
to interact with α-thrombin in the absence or presence of protease-acti
vated receptor 1. Biochemistry 47, 13279–13286
15. Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., An
drade-Gordon, P., Covic, L., and, Kuliopulos, A. (2006) Blocking the pro
tease-activated receptor 1–4 heterodimer in platelet-mediated thrombo
sis. Circulation 113, 1244–1254
16. Holinast, M., Voss, B., Bilodeau, M. L., McLaughlin, J. N., Cletor, J., and,
Hamm, H. E. (2006) PAR4, but not PAR1, signals human platelet aggrega
tion via Ca2+ mobilization and synergistic P2Y12 receptor activation. J.
Biol. Chem. 281, 26665–26674
17. Voss, B., McLaughlin, J. N., Holinast, M., Zent, R., and, Hamm, H. E.
(2007) PAR1, but not PAR4, activates human platelets through a G protein
phosphoinositide-3 kinase signaling axis. Mol. Pharmacol. 71, 1399–1406
Mapping PAR4 Homodimer Interface

18. Fälker, K., Haglund, L., Gunnarsson, P., Nylander, M., Lindahl, T. L., and Grenegård, M. (2011) Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets. Biochim. J. 436, 469–480
19. Kahn, M. L., Nakanishi-Matsui, M., Shapiro, M. J., Ishihara, H., and Coughlin, S. R. (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103, 879–887
20. Covic, L., Gresser, A. L., and Kuliopulos, A. (2000) Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39, 5458–5467
21. Covic, L., Singh, C., Smith, H., and Kuliopulos, A. (2002) Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb. Haemost. 87, 722–727
22. Mazharian, A., Roger, S., Berrou, E., Adam, F., Kauskot, A., Nurden, P., Jandrot-Perrus, M., and Bryckaert, M. (2007) Role of the PAR4 receptor in sepsis-induced vascular damage. Curr. Opin. Pharmacol. 7, 25–29
23. Strande, J. L., Hsu, A., Su, J., Fu, X., Gross, G. J., and Baker, J. E. (2008) PAR1 in smooth muscle cells. Thromb. Haemost. 100, 1045–1054
24. Russell, F. A., Veldhoen, V. E., Tchitchkan, D., and McDougall, J. J. (2010) Proteinase-activated receptor-4 (PAR4) activation leads to sensitization of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism. J. Neurophysiol. 103, 155–163
25. Vellani, V., Kinsey, A. M., Prandini, M., Hechtfischer, S. C., Reh, P., Magherini, P. C., Giacomoni, C., and McNaughton, P. A. (2010) Protease activated receptors 1 and 4 sensitize TRPV1 in nociceptive neurons. Mol. Pain 6, 61
26. Dangwal, S., Rauch, B. H., Gensch, T., Dai, L., Breit, A., and Bouvier, M. (2002) Dopamine D2 receptors form higher order oligomers for G-protein-coupled receptors. EMBO J. 27, 2293–2304
27. Vegh, M., Tóth, M., and Jászberényi, T. (1999) The transmembrane domain promotes signal transduction through the G protein-coupled receptor. Methods Mol. Biol. 96, 65–77
28. Mercier, J. F., Salahpour, A., Angers, S., Breit, A., and Bouvier, M. (2002) Quantitative assessment of β1- and β2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 277, 44925–44931
29. Herrick-Davis, K., Grinde, E., and Mazurkiewicz, J. E. (2004) Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells. Biochemistry 43, 13963–13971
30. Adamus, G., Zam, Z. S., Arendt, A., Palczewski, K., Mcdowell, J. H., and Hargrave, P. A. (1991) Anti-rhodopsin monoclonal antibodies of defined specificity. Characterization and application. Vision Res. 31, 17–31
31. Nieman, M. T., Warnock, M., Hasan, A. A., Mahdi, F., Lucchesi, B. R., Brown, N. J., Murphey, L. J., and Schmaier, A. H. (2004) The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J. Pharmacol. Exp. Ther. 311, 492–501
32. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440–3450
33. Notredame, C., Higgins, D. G., and Heringa, J. (2000) T-Coffee. A novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 302, 205–217
34. Poiriot, O., O’Toole, E., and Notredame, C. (2003) Tcoffee@igs. A web server for computing, evaluating and combining multiple sequence alignments. Nucleic Acids Res. 31, 3503–3506
35. Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006) The SWISS-MODEL workspace. A web-based environment for protein structure homology modeling. Bioinformatics 22, 195–200
36. Bordoli, L., Kiefer, F., Arnold, K., Benkert, P., Battey, J., and Schwede, T. (2009) Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 4, 1–13
37. Schwede, T., Kopp, J., Guex, N., and Peitsch, M. C. (2003) SWISS-MODEL. An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381–3385
38. Woolf, D. S. (2005) Platelet G protein-coupled receptors in hemostasis and thrombosis. J. Thromb. Haemost. 3, 2193–2200
39. Park, P. S., Filipke, S., Wells, J. W., and Palczewski, K. (2004) Oligomerization of G protein-coupled receptors. Past, present, and future. Biochemistry 43, 15643–15656
40. Pin, J. P., Neubig, R., Bouvier, M., Devi, L., Filizola, M., Javitch, J. A., Lobse, M. I., Milligan, G., Palczewski, K., Parmentier, M., and Spedding, M. (2007) International Union of Basic and Clinical Pharmacology. LVIII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 59, 5–13
41. Whorton, M. R., Bokoch, M. P., Rasmussen, S. G., Huang, B., Zare, R. N., Koblika, B., and Sunahara, R. K. (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U.S.A. 104, 7682–7687
42. Whorton, M. R., Jastrzebska, B., Park, P. S., Fotiadis, D., Engel, A., Palczewski, K., and Sunahara, R. K. (2008) Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J. Biol. Chem. 283, 4387–4394
43. Fotiadis, D., Jastrzebska, B., Philippsen, A., Müller, D. I., Palczewski, K., and Engel, A. (2006) Structure of the rhodopsin dimer. A working model for G-protein-coupled receptors. Curr. Opin. Struct. Biol. 16, 252–259
44. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin. A G protein-coupled receptor. Science 289, 739–745
45. Jastrzebska, B., Ringler, P., Lodowski, D. T., Moiseenkova-Bell, V., Golczak, M., Müller, S. A., Palczewski, K., and Engel, A. (2011) Rhodopsin-transducin heteropentamer. Three-dimensional structure and biochemical characterization. J. Struct. Biol. 176, 387–394
46. Cherezov, V., Abola, E., and Stevens, R. C. (2010) Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets. Methods Mol. Biol. 654, 141–168
47. Huber, O., Kemler, R., and Langosch, D. (1999) Mutations affecting transmembrane segment interactions impair adhesiveness of E-cadherin. J. Cell Sci. 112, 4415–4423
48. Kubatczyk, K. F., Ruan, W., Gurezka, R., Cohen, J., Ketteler, R., Watowich, S. S., Neumann, D., Langosch, D., and Klingmüller, U. (2001) Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr. Biol. 11, 110–115
49. Ruan, W., Becker, V., Klingmüller, U., and Langosch, D. (2004) The interaction between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipper. J. Biol. Chem. 279, 3273–3279
50. Noordeen, N. A., Carafoli, F., Hohenester, E., Horton, M. A., and Leitinger,
B. (2006) A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1. J. Biol. Chem. 281, 22744–22751

57. Guo, W., Shi, L., Filizola, M., Weinstein, H., and Javitch, J. A. (2005) Cross-talk in G protein-coupled receptors. Changes at the transmembrane homodimer interface determine activation. Proc. Natl. Acad. Sci. U.S.A. 102, 17495–17500

58. Wang, H. X., and Konopka, J. B. (2009) Identification of amino acids at two dimer interface regions of the α-factor receptor (Ste2). Biochemistry 48, 7132–7139

59. Prinster, S. C., Hague, C., and Hall, R. A. (2005) Heterodimerization of G protein-coupled receptors. Specificity and functional significance. Pharmacol. Rev. 57, 289–298

60. McMillin, S. M., Heusel, M., Liu, T., Costanzi, S., and Wess, J. (2011) Structural basis of M3 muscarinic receptor dimer/oligomer formation. J. Biol. Chem. 286, 28584–28598

61. Holinstat, M., Voss, B., Bilodeau, M. L., and Hamm, H. E. (2007) Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway. Mol. Pharmacol. 71, 686–694

62. Augé, C., Balz-Hara, D., Steinhoff, M., Vergnolle, N., and Cenac, N. (2009) Protease-activated receptor-4 (PAR 4). A role as inhibitor of visceral pain and hypersensitivity. Neurogastroenterol. Motil. 21, 1189-e107

63. Simon, D. I., and Schmaier, A. H. (2007) Sweet and sticky. Diabetic platelets, enhanced reactivity, and cardiovascular risk. J. Am. Coll. Cardiol. 50, 1548–1550